1. Key Insights 2. Catheter-Related Blood Stream Infection (CRBSI) Market Overview at a Glance 2.1. Total Market Share (%) Distribution of CRBSI in 2017 2.2. Total Market Share (%) Distribution of CRBSI in 2028 3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview 3.1. Introduction 3.2. Difference between CLABSI and CRBSI 3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI) 3.3.1. Micro-organisms 3.3.2. Intravascular Devices 3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI) 3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI) 3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI) 3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI) 3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI 3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) 3.7.3. British Intestinal Failure Alliance (BIFA): 3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Incident Population of CRBSI in the 7MM 4.3. Total Diagnosed Incident Population of CRBSI in the 7MM 4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM 4.5. Some KOL Insights 5. United States Epidemiology 5.1. Assumptions and Rationale 5.2. Total Incident Population of CRBSI in the United States 5.3. Total Diagnosed Incident Population of CRBSI in the United States 5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States 6. EU5 Epidemiology 6.1. Germany Epidemiology 6.1.1. Assumptions and Rationale 6.1.2. Total Incident Population of CRBSI in Germany 6.1.3. Total Diagnosed Incident Population of CRBSI in Germany 6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany 6.2. France Epidemiology 6.2.1. Assumptions and rationale 6.2.2. Total Incident Population of CRBSI in France 6.2.3. Total Diagnosed Incident Population of CRBSI in France 6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France 6.3. Italy Epidemiology 6.3.1. Assumptions and Rationale 6.3.2. Total Incident Population of CRBSI in Italy 6.3.3. Total Diagnosed Incident Population of CRBSI in Italy 6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy 6.4. Spain Epidemiology 6.4.1. Assumptions and Rationale 6.4.2. Total Incident Population of CRBSI in Spain 6.4.3. Total Diagnosed Incident Population of CRBSI in Spain 6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain 6.5. United Kingdom Epidemiology 6.5.1. Assumptions and Rationale 6.5.2. Total Incident Population of CRBSI in the United Kingdom 6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom 6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom 7. Japan Epidemiology 7.1. Assumptions and Rationale 7.2. Total Incident Population of CRBSI in Japan 7.3. Total Diagnosed Incident Population of CRBSI in Japan 7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan 8. Total Treatment Algorithm, Current Treatment, and Medical Practices 8.1. Treatment of Catheter-Related Bloodstream Infection (CRBSI) 8.1.1. General 8.1.2. Short-term Central Venous or Arterial CRBSI 8.1.3. Long-term Central Venous CRBSI 8.2. Treatment Guidelines for Catheter-related bloodstream infection (CRBSI) 8.2.1. Infectious Diseases Society of America: Guidelines for the pathogen-specific treatment 8.2.2. Spanish Society of Infectious Diseases: Treatment of CRBSIs 8.3. Prevention Guidelines of Catheter-Related Bloodstream Infection (CRBSI) 8.3.1. Infectious Diseases Society of America (IDSA), Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC): 8.3.2. European Renal Best Practice (ERBP) Recommendations for Prevention of CRBSIs 9. Unmet Needs 10. Marketed Products 10.1. Neutrolin: CorMedix 10.1.1. Product Description 10.1.2. Mechanism of Action 10.1.3. Regulatory milestones 10.1.4. Clinical Development 10.1.5. Clinical Trials Information 10.1.6. Safety and Efficacy 10.1.7. Product Profile 10.2. Taurosept: Geistlich Pharma 10.2.1. Product Description 10.2.2. Mechanism of Action 10.2.3. Regulatory milestones 10.2.4. Clinical Development 10.2.5. Safety and Efficacy 10.2.6. Product Profile 10.3. Taurolock: TauroPharm GmbH 10.3.1. Product Description 10.3.2. Mechanism of Action 10.3.3. Regulatory Milestones 10.3.4. Clinical Development 10.3.5. Clinical Trials Information 10.3.6. Safety and Efficacy 10.3.7. Product Profile 10.4. IntraLock: Fresenius Medical Care 10.4.1. Product Description 10.4.2. Mechanism of Action 10.4.3. Regulatory Milestones 10.4.4. Advantages 10.4.5. Product Profile 11. Off-label Drugs 11.1. Antibacterials 11.1.1. Daptomycin 11.1.1.1. Product Description 11.1.1.2. Mechanism of Action 11.1.1.3. Generic Availability 11.1.1.4. Clinical Trials Information 11.1.2. Vancomycin 11.1.2.1. Product Description 11.1.2.2. Mechanism of Action 11.1.2.3. Generic Availability 11.1.3. Cefazolin 11.1.3.1. Product Description 11.1.3.2. Mechanism of Action 11.1.3.3. Generic Availability 11.1.4. Ampicillin 11.1.4.1. Product Description 11.1.4.2. Mechanism of Action 11.1.4.3. Generic Availability 11.1.5. Ciprofloxacin 11.1.5.1. Product Description 11.1.5.2. Mechanism of Action 11.1.5.3. Generic Availability 11.1.6. Amikacin 11.1.6.1. Product Description 11.1.6.2. Mechanism of Action 11.1.6.3. Generic Availability 11.1.7. Teicoplanin 11.1.7.1. Product Description 11.1.7.2. Mechanism of Action 11.1.7.3. Generic Availability 11.2. Antifungals 11.2.1. Fluconazole 11.2.1.1. Product Description 11.2.1.2. Mechanism of Action 11.2.1.3. Generic Availability 11.2.2. Amphotericin B 11.2.2.1. Product Description 11.2.2.2. Mechanism of Action 11.2.2.3. Generic Availability 12. Emerging Therapies 12.1. Mino-Lok: Citius Pharmaceuticals 12.1.1. Product Description 12.1.2. Other Developmental Activities 12.1.3. Clinical Development 12.1.4. Product Profile 13. CRBSI: 7MM Market Analysis 13.1. Key Findings 13.2. Market Size of CRBSI in 7MM 13.3. Market Size of CRBSI by Therapies in the 7MM 14. United States: Market Outlook 14.1. United States Market Size 14.1.1. Total Market size of CRBSI 14.1.2. Market Size of CRBSI by Therapies in the US 15. EU-5 countries: Market Outlook 15.1. Germany Market Size 15.1.1. Total Market size of CRBSI 15.1.2. Market Size of CRBSI by therapies in Germany 15.2. France Market Size 15.2.1. Total Market size of CRBSI 15.2.2. Market Size of CRBSI by therapies in France 15.3. Italy Market Size 15.3.1. Total Market size of CRBSI 15.3.2. Market Size of CRBSI by therapies in Italy 15.4. Spain Market Size 15.4.1. Total Market size of CRBSI 15.4.2. Market Size of CRBSI by therapies in Spain 15.5. United Kingdom Market Size 15.5.1. Total Market size of CRBSI 15.5.2. Market Size of CRBSI by therapies in the UK 16. Japan Market Outlook 16.1. Japan Market Size 16.1.1. Total Market size of CRBSI 16.1.2. Market Size of CRBSI by therapies in Japan 17. Market Drivers 18. Market Barriers 19. Appendix 19.1. Report Methodology 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight

TABLE 1: TERMINOLOGY: CLABSI OR CRBSI TABLE 2: VARIOUS RISK FACTORS OF CRBSI TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028) TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028) TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017–2028) TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017–2028) TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017–2028) TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017–2028) TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028) TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028) TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017–2028) TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028) TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028) TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017–2028) TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028) TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028) TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017–2028) TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028) TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028) TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017–2028) TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028) TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028) TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017–2028) TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028) TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028) TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017–2028) TABLE 27: THE MAIN ANTIMICROBIAL DRUG AND DOSAGE REGIMENS THAT SHOULD BE USED FOR CATHETER-RELATED INFECTIONS. TABLE 28: NEUTROLIN (CRMD003), CLINICAL TRIAL DESCRIPTION, 2019 TABLE 29: TAUROSEPT, CLINICAL TRIAL DESCRIPTION, 2019 TABLE 30: TAUROLOCK, CLINICAL TRIAL DESCRIPTION, 2019 TABLE 31: GENERIC PRODUCTS OF DAPTOMYCIN IN THE 7MM TABLE 32: DAPTOMYCIN, CLINICAL TRIAL DESCRIPTION, 2019 TABLE 33: GENERIC PRODUCTS OF VANCOMYCIN IN THE 7MM TABLE 34: GENERIC PRODUCTS OF CEFAZOLIN IN THE 7MM TABLE 35: GENERIC PRODUCTS OF AMPICILLIN IN THE 7MM TABLE 36: GENERIC PRODUCTS OF CIPROFLOXACIN AVAILABLE IN THE 7MM TABLE 37: GENERIC PRODUCTS OF AMIKACIN IN THE 7MM TABLE 38: GENERIC PRODUCTS OF TEICOPLANIN IN THE 7MM TABLE 39: GENERIC PRODUCTS OF FLUCONAZOLE IN THE 7MM TABLE 40: GENERIC PRODUCTS OF AMPHOTERICIN B IN THE 7MM TABLE 41: MINO-LOK, CLINICAL TRIAL DESCRIPTION, 2019 TABLE 42: MARKET SIZE OF CATHETER RELATED BLOODSTREAM INFECTION (CRBSI) IN THE 7MM IN USD MILLION (2017–2028) TABLE 43: MARKET SIZE OF CRBSI BY THERAPIES IN THE 7MM, IN USD MILLION (2017–2028) TABLE 44: THE US MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 45: MARKET SIZE OF CRBSI BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017–2028) TABLE 46: GERMANY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 47: MARKET SIZE OF CRBSI BY THERAPIES IN GERMANY, IN USD MILLION (2017–2028) TABLE 48: FRANCE MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 49: MARKET SIZE OF CRBSI BY THERAPIES IN FRANCE, IN USD MILLION (2017–2028) TABLE 50: ITALY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 51: MARKET SIZE OF CRBSI BY THERAPIES IN ITALY, IN USD MILLION (2017–2028) TABLE 52: SPAIN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 53: MARKET SIZE OF CRBSI BY THERAPIES IN SPAIN, IN USD MILLION (2017–2028) TABLE 54: THE UK MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 55: MARKET SIZE OF CRBSI BY THERAPIES IN THE UK, IN USD MILLION (2017–2028) TABLE 56: JAPAN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028) TABLE 57: MARKET SIZE OF CRBSI BY THERAPIES IN THE JAPAN, IN USD MILLION (2017–2028) Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion Figure 2: Important pathogenic determinants of catheter-related infections Figure 3: Potential sources of infection of a percutaneous intravascular device Figure 4: Total Incident Population of CRBSI in the 7MM (2017–2028) Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017–2028) Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017–2028) Figure 7: Total Incident Population of CRBSI in the US (2017–2028) Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017–2028) Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028) Figure 10: Total Incident Population of CRBSI in Germany (2017–2028) Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017–2028) Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028) Figure 13: Total Incident Population of CRBSI in France (2017–2028) Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017–2028) Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028) Figure 16: Total Incident Population of CRBSI in Italy (2017–2028) Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017–2028) Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028) Figure 19: Total Incident Population of CRBSI in Spain (2017–2028) Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017–2028) Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028) Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017–2028) Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028) Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028) Figure 25: Total Incident Population of CRBSI in Japan (2017–2028) Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017–2028) Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028) Figure 28: Flow chart Summarizing Approaches for Systemic Antibiotic Treatment. Figure 29: Approach to the management of patients with short-term central venous catheter-related or arterial catheter-related bloodstream infection. CFU, colony-forming units; S. aureus, Staphylococcus aureus. Figure 30: Approach to the treatment of a patient with a long-term central venous catheter (CVC) or a port (P)-related bloodstream infection. Figure 31: Approach to the treatment of a patient with confirmed CRBSI. Figure 32: Unmet Needs Figure 33: Market Size of Catheter-Related Bloodstream Infection (CRBSI) in the 7MM in USD Million (2017–2028) Figure 34: Market Size of CRBSI by therapies in the 7MM, in USD Million (2017–2028) Figure 35: Market Size of CRBSI in the US, USD Millions (2017–2028) Figure 36: Market Size of CRBSI by therapies in the United States, in USD Million (2017–2028) Figure 37: Market Size of CRBSI in Germany, USD Millions (2017–2028) Figure 38: Market Size of CRBSI by therapies in Germany, in USD Million (2017–2028) Figure 39: Market Size of CRBSI in France, USD Millions (2017–2028) Figure 40: Market Size CRBSI by therapies in France, in USD Million (2017–2028) Figure 41: Market Size of CRBSI in Italy, USD Millions (2017–2028) Figure 42: Market Size of CRBSI by therapies in Italy in USD Million (2017–2028) Figure 43: Market Size of CRBSI in Spain, USD Millions (2017–2028) Figure 44: Market Size of CRBSI by therapies in Spain in USD Million (2017–2028) Figure 45: Market Size of CRBSI in the UK, USD Millions (2017–2028) Figure 46: Market Size of CRBSI by therapies in the UK in USD Million (2017–2028) Figure 47: Market Size of CRBSI in Japan, USD Millions (2017–2028) Figure 48: Market Size of CRBSI by therapies in Japan in USD Million (2017–2028) Figure 49: Market Drivers Figure 50: Market Barriers

• CorMedix • Geistlich Pharma • TauroPharm GmbH • Fresenius Medical Care • Citius Pharmaceuticals